Hoth Therapeutics Inc (HOTH) concluded trading on Wednesday at a closing price of $0.98, with 6.02 million shares of worth about $5.9 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 11.18% during that period and on April 03, 2025 the price saw a gain of about 0.38%. Currently the company’s common shares owned by public are about 13.17M shares, out of which, 13.11M shares are available for trading.
Stock saw a price change of -4.08% in past 5 days and over the past one month there was a price change of -21.10%. Year-to-date (YTD), HOTH shares are showing a performance of 30.78% which decreased to -31.10% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.58 but also hit the highest price of $3.80 during that period. The average intraday trading volume for Hoth Therapeutics Inc shares is 8.92 million. The stock is currently trading -7.76% below its 20-day simple moving average (SMA20), while that difference is down -11.73% for SMA50 and it goes to 3.05% higher than SMA200.
Hoth Therapeutics Inc (NASDAQ: HOTH) currently have 13.17M outstanding shares and institutions hold larger chunk of about 1.85% of that.
The stock has a current market capitalization of $12.89M and its 3Y-monthly beta is at 0.52. It has posted earnings per share of -$1.34 in the same period. It has Quick Ratio of 9.20 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HOTH, volatility over the week remained 7.27% while standing at 9.03% over the month.
Stock’s fiscal year EPS is expected to rise by 46.59% while it is estimated to increase by 39.01% in next year. EPS is likely to shrink at an annualized rate of 27.65% for next 5-years, compared to annual growth of 27.96% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by The Benchmark Company on October 15, 2019 offering a Speculative buy rating for the stock and assigned a target price of $10 to it.
